Terry S. Elton

Terry S. Elton studies how leukemia cells become resistant to chemotherapy drugs that target an enzyme called DNA topoisomerase II, which is important for how anticancer drugs like etoposide work. His lab uses techniques such as CRISPR/Cas9 gene editing and studies of RNA processing (including microRNAs and 'intronic polyadenylation,' a process affecting how genetic messages are cut and used) to understand and potentially reverse drug resistance in K562 human leukemia cells. This work aims to identify molecular mechanisms that could be targeted to make cancer drugs more effective for patients whose tumors have become resistant.

Publication output has remained modest and relatively steady over the last decade, with a peak of 6 papers in 2022 and averaging about 2 papers per year over the last five years.

Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026